306 research outputs found
Recommended from our members
Osimertinib plus Ramucirumab: The Best of Both Worlds?
No full textBoth osimertinib and the combination of erlotinib plus ramucirumab are approved for initial therapy of advanced EGFR mutation-positive non-small cell lung cancer. Osimertinib is also approved in previously treated T790M mutation-positive patients. The accompanying article reports on a study combining osimertinib with ramucirumab.See related article by Yu et al., p. 992
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study
No full text
Are lung adenocarcinoma mutations shaping the immune microenvironment?
No full textInternational audienc
- …
